Corton Capital Inc. acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 15,973 shares of the company's stock, valued at approximately $470,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Strs Ohio grew its position in Denali Therapeutics by 9.1% during the second quarter. Strs Ohio now owns 33,700 shares of the company's stock worth $991,000 after buying an additional 2,800 shares during the period. Pier 88 Investment Partners LLC boosted its position in Denali Therapeutics by 130,700.0% during the second quarter. Pier 88 Investment Partners LLC now owns 13,080 shares of the company's stock worth $385,000 after purchasing an additional 13,070 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Denali Therapeutics by 581.0% in the second quarter. Nisa Investment Advisors LLC now owns 17,816 shares of the company's stock valued at $524,000 after purchasing an additional 15,200 shares during the last quarter. Swiss National Bank increased its position in shares of Denali Therapeutics by 8.1% in the first quarter. Swiss National Bank now owns 187,700 shares of the company's stock valued at $6,038,000 after buying an additional 14,000 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its stake in shares of Denali Therapeutics by 29.4% during the 2nd quarter. Eagle Asset Management Inc. now owns 263,704 shares of the company's stock worth $7,760,000 after buying an additional 59,854 shares during the last quarter. 74.56% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Marc Tessier-Lavigne sold 8,748 shares of Denali Therapeutics stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $30.20, for a total transaction of $264,189.60. Following the sale, the director now directly owns 1,901,608 shares in the company, valued at $57,428,561.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 48,748 shares of company stock valued at $1,490,190. Insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

Denali Therapeutics Stock Performance

Shares of DNLI stock traded down $0.49 during trading hours on Wednesday, hitting $29.97. 11,914 shares of the company were exchanged, compared to its average volume of 600,947. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -12.17 and a beta of 1.46. Denali Therapeutics Inc. has a one year low of $20.24 and a one year high of $48.46. The business's 50-day simple moving average is $30.21 and its two-hundred day simple moving average is $30.21.

Denali Therapeutics (NASDAQ:DNLI – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.01). The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $10.06 million. Denali Therapeutics had a negative return on equity of 33.85% and a negative net margin of 273.34%. As a group, analysts anticipate that Denali Therapeutics Inc. will post -2.6 EPS for the current fiscal year.

About Denali Therapeutics

(Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Further Reading

• Get a free copy of the StockNews.com research report on Denali Therapeutics (DNLI)
• Institutions Sell The Rallies In Toll Brothers Stock
• Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
• How to Play Apple and Amazon Heading in 2023
• Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
• Should The Bancorp Make Your Small-Cap Watchlist for 2023?

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.